Down 27%: Impax Labs' Massive Drop

Shares of Impax Laboratories (NASDAQ: IPXL  ) spiraled down more than 25% today after the company reported that the FDA continues to have concerns with one of its manufacturing facilities. This issue has already held up the potential approval of the company's Parkinson's disease drug, Rytary -- a therapeutic that the company has partially licensed to pharma stalwart GlaxoSmithKline (NYSE: GSK  ) -- which was rejected by the FDA in January. In the following video, health care analyst Max Macaluso sheds light on this story.

If you're seeking companies with huge potential, our new free report "Middle-Class Millionaire-Makers: 3 Stocks Wall Street's Too Rich to Notice" highlights three less-than-luxurious stocks the market is ignoring. Click here to read it now.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2294675, ~/Articles/ArticleHandler.aspx, 12/19/2014 4:27:01 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement